Stephen Hoge Sells 15,000 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 15,000 shares of Moderna stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $138.16, for a total transaction of $2,072,400.00. Following the transaction, the president now directly owns 1,457,089 shares in the company, valued at approximately $201,311,416.24. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Stephen Hoge also recently made the following trade(s):

• On Wednesday, May 29th, Stephen Hoge sold 341 shares of Moderna stock. The stock was sold at an average price of $144.50, for a total transaction of $49,274.50.
• On Friday, May 10th, Stephen Hoge sold 255 shares of Moderna stock. The stock was sold at an average price of $120.96, for a total transaction of $30,844.80.
• On Monday, April 15th, Stephen Hoge sold 15,000 shares of Moderna stock. The stock was sold at an average price of $105.02, for a total transaction of $1,575,300.00.

Moderna Price Performance

NASDAQ MRNA opened at $133.27 on Thursday. The company has a quick ratio of 3.91, a current ratio of 4.03 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $170.47. The company has a market capitalization of $51.07 billion, a PE ratio of -8.50 and a beta of 1.54. The firm’s 50 day moving average is $130.56 and its 200-day moving average is $109.54.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. The business had revenue of $167.00 million for the quarter, compared to the consensus estimate of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The firm’s revenue for the quarter was down 91.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.19 earnings per share. Equities research analysts anticipate that Moderna, Inc. will post -7.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Moderna

A number of institutional investors have recently added to or reduced their stakes in MRNA. Vanguard Group Inc. increased its holdings in Moderna by 22.6% during the fourth quarter. Vanguard Group Inc. now owns 33,907,072 shares of the company’s stock worth $3,372,058,000 after buying an additional 6,248,623 shares during the last quarter. Norges Bank acquired a new position in Moderna during the fourth quarter worth $347,565,000. The Manufacturers Life Insurance Company increased its holdings in Moderna by 77.3% during the third quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock worth $400,367,000 after buying an additional 1,690,341 shares during the last quarter. Wellington Management Group LLP boosted its position in Moderna by 28.8% during the fourth quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock worth $718,584,000 after purchasing an additional 1,614,460 shares during the period. Finally, Invesco Ltd. boosted its position in Moderna by 19.8% during the third quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock worth $322,887,000 after purchasing an additional 517,683 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MRNA has been the topic of several recent analyst reports. HSBC reissued a “reduce” rating and set a $86.00 price objective (up previously from $75.00) on shares of Moderna in a research note on Monday, February 26th. Jefferies Financial Group restated a “buy” rating and set a $125.00 target price on shares of Moderna in a report on Tuesday, April 9th. Canaccord Genuity Group raised their target price on shares of Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a report on Friday, May 3rd. Needham & Company LLC restated a “hold” rating on shares of Moderna in a report on Monday, June 3rd. Finally, Oppenheimer raised their target price on shares of Moderna from $163.00 to $179.00 and gave the stock an “outperform” rating in a report on Wednesday, June 12th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $129.02.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.